Aclaris Therapeutics reports Q2 EPS (13c), consensus (13c)

Reports Q2 revenue $1.78M, consensus $1.29M. As of June 30, 2025, Aclaris had cash, cash equivalents and marketable securities of $180.9M vs. $203.9M as of December 31, 2024. The company believes that its cash, cash equivalents and marketable securities will be sufficient to fund its operations into the second half of 2028. “Aclaris is in a period of strong execution throughout the business as we advance our innovative therapies toward our goal of improving therapeutic options for patients with certain I&I diseases,” stated CEO Neal Walker. “For example, the results from the single arm Phase 2a clinical trial of our ITK/JAK3 inhibitor ATI-2138 represent a significant achievement for our ITK franchise by both confirming the strong tolerability profile and mechanism of ATI-2138 in AD ahead of our planned alopecia areata clinical trial and validating ITK as an important therapeutic target. Importantly, with an expected cash runway that funds our operations into the second half of 2028, we have sufficient capital to execute our strategic plan. We are also exploring additional non-dilutive opportunities to extend our cash runway even further.”